EcoDrugPlus

Adam Metallopeptidase Domain 17a

Ensembl ID : ENSOMYG00000029732
Gene Symbol: ADAM17A
2 Cross references
201 Possible Orthologues:

Adam Metallopeptidase With Thrombospondin Type 1 Motif 5

Ensembl ID : ENSOMYG00000038992
Gene Symbol: ADAMTS5
1 Cross references
193 Possible Orthologues:

Adam Metallopeptidase With Thrombospondin Type 1 Motif 5

Ensembl ID : ENSOMYG00000011879
Gene Symbol: ADAMTS5
1 Cross references
192 Possible Orthologues:

Apex Nuclease (Multifunctional Dna Repair Enzyme) 1

Ensembl ID : ENSOMYG00000010104
Gene Symbol: APEX1
1 Cross references
206 Possible Orthologues:

Apex Nuclease (Multifunctional Dna Repair Enzyme) 1

Ensembl ID : ENSOMYG00000010983
Gene Symbol: APEX1
1 Cross references
206 Possible Orthologues:

Aph1b Gamma Secretase Subunit

Ensembl ID : ENSOMYG00000076821
Gene Symbol: APH1B
1 Cross references
183 Possible Orthologues:

Atp Binding Cassette Subfamily C Member 1

Ensembl ID : ENSOMYG00000047890
Gene Symbol: ABCC1
1 Cross references
198 Possible Orthologues:

Atp-Binding Cassette, Sub-Family C (Cftr/mrp), Member 8

Ensembl ID : ENSOMYG00000025242
Gene Symbol: ABCC8
1 Cross references
223 Possible Orthologues:

Atp-Binding Cassette, Sub-Family C (Cftr/mrp), Member 8

Ensembl ID : ENSOMYG00000039065
Gene Symbol: ABCC8
1 Cross references
223 Possible Orthologues:

Atp-Binding Cassette, Sub-Family C (Cftr/mrp), Member 9

Ensembl ID : ENSOMYG00000026375
Gene Symbol: ABCC9
1 Cross references
220 Possible Orthologues:

Atp-Binding Cassette, Sub-Family C (Cftr/mrp), Member 9

Ensembl ID : ENSOMYG00000065922
Gene Symbol: ABCC9
1 Cross references
219 Possible Orthologues:

Atpase H+/k+ Transporting Subunit Beta

Ensembl ID : ENSOMYG00000063533
Gene Symbol: ATP4B
1 Cross references
183 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).